Multiple oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.
|Articles|December 8, 2014
Brentuximab Vedotin in Combination With Bendamustine for Patients With Hodgkin Lymphoma
Author(s)Ann S. LaCasce, MD
Ann S. LaCasce, MD, discusses the combination of brentuximab vedotin and bendamustine for the treatment of patients with Hodgkin lymphoma.
Advertisement
Clinical Pearls
Ann S. LaCasce, MD, assistant professor of medicine, Harvard Medical School, lymphoma program, Dana-Farber Cancer Institute, discusses the combination of brentuximab vedotin and bendamustine for the treatment of patients with Hodgkin lymphoma.
- The study analyzed 53 patients with Hodgkin lymphoma who were in first relapse or had primary refractory disease after initial therapy.
- Patients were treated with brentuximab vedotin in combination with bendamustine.
- The overall response rate was 96%.
- 83% of patients achieved a complete remission.
- Some unexpected infusion-related toxicity was observed.
<<<
Advertisement
Related to this article
Phase 2b data show iopofosine I-131 drives deep, durable responses in relapsed Waldenström macroglobulinemia after BTK inhibitors, with manageable cytopenias.
FDA accepts updated tab-cel BLA for EBV+ PTLD after transplant, adding ALLELE data; PDUFA decision set for March 31, 2027.
Preview the late-breaking studies at ESMO Congress 2026, from KRAS inhibitors and ADCs to bispecifics and perioperative immunotherapy across tumor types.
Real-world German MINT data show mogamulizumab delivers durable responses, ~20-month PFS, manageable safety, and improved quality of life in MF and Sézary syndrome.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
3
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
4
Rusfertide Improves Hematocrit Control, Reduces Phlebotomy in Polycythemia Vera
5